MIRA Pharmaceuticals financials
$0.8715−3.52%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$10.5M | -$8.0M | -$8.5M |
| Net income | -$32.0M | -$7.9M | -$12.0M |
| Net margin | — | — | — |
| Diluted EPS | $-1.35 | $-0.51 | $-0.85 |
| EBITDA | -$10.5M | -$8.0M | -$8.5M |
| Operating cash flow | -$4.7M | -$5.6M | -$4.5M |
| Free cash flow | -$4.7M | -$5.6M | -$4.5M |
| Diluted shares | 23.7M | 15.4M | 13.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $6.3M | $2.8M | $4.6M |
| Short-term investments | $4.7M | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $11.1M | $2.9M | $4.9M |
| Total liabilities | $702.1K | $723.3K | $558.1K |
| Shareholders' equity | $10.4M | $2.2M | $4.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology